ANTIBODIES TO BOTH RO52 AND RO60 DEFINE A SUBSET OF SJOGREN'S MOST SUITABLE FOR CLINICAL TRIALS OF AGENTS TARGETING LYMPHOPROLIFERATIONS

Copy For Citation

ARMAĞAN B., Robinson S., Bazoberry A., Grader-Beck T., Baer A.

Annual European Congress of Rheumatology (EULAR), Madrid, Spain, 12 - 15 June 2019, vol.78, pp.1160, (Summary Text)

• Publication Type: Conference Paper / Summary Text
• Volume: 78
• Doi Number: 10.1136/annrheumdis-2019-eular.3387
• City: Madrid
• Country: Spain
• Page Numbers: pp.1160
• Hacettepe University Affiliated: Yes